Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immuron Limited ( (AU:IMC) ) just unveiled an announcement.
Immuron Limited announced the quotation of 45,472,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of previously announced transactions. This move is expected to enhance the company’s market presence and provide additional capital for its ongoing projects, potentially impacting its operational capabilities and stakeholder interests positively.
The most recent analyst rating on (AU:IMC) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases.
Average Trading Volume: 591,318
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$18.34M
See more insights into IMC stock on TipRanks’ Stock Analysis page.